Press Release

Positive Three-Year Antibody Persistence Data for Single-Shot Chikungunya Vaccine IXCHIQ® Read more
lab testing

Advancing Vaccines
For Better Lives

Welcome to Valneva

We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We have leveraged our expertise and capabilities both to commercialize three vaccines, including the world’s first and only chikungunya vaccine, and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, Shigella and Zika.

Learn More

Check out our 2023 Annual Business Report

Learn More

Follow Us